We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Metabolic Disturbances Characterize Patients with Idiopathic Intracranial Hypertension

By LabMedica International staff writers
Posted on 09 Sep 2022
Image: Hypertension sign and symptoms information (Photo courtesy of www.123rf.com)
Image: Hypertension sign and symptoms information (Photo courtesy of www.123rf.com)

Individuals suffering from idiopathic intracranial hypertension are distinguishable by irregularities in the distribution of metabolites that can be detected in CSF, serum, and urine.

Idiopathic intracranial hypertension (IIH) is a condition characterized by increased pressure around the brain that appears without a detectable cause. The main symptoms are headache, vision problems, ringing in the ears, and shoulder pain. Complications may include vision loss. Risk factors include being overweight or a recent increase in weight. Tetracycline may also trigger the condition. Diagnosis is based on symptoms and a high opening pressure found during a lumbar puncture with no specific cause found on a brain scan. Previous studies from investigators at the University of Birmingham (United Kingdom) demonstrated that IIH also featured metabolic disturbances.

In the current study, the investigators compared women aged 18-55 years with active IIH to a sex, age, and body mass index matched control group. IIH participants were identified from neurology and ophthalmology clinics and underwent a prospective intervention to induce disease remission through weight loss with re-evaluation at 12 months.

The investigators evaluated the metabolomic profile in CSF, serum, and urine of patients with IIH compared to control subjects and measured changes in metabolism associated with clinical markers of disease activity and treatment. Clinical assessments included lumbar puncture, headache, eye examination for papilledema, and other visual measurements. Spectra of CSF, serum, and urine metabolites were acquired utilizing proton nuclear magnetic resonance spectroscopy.

Results revealed that urea was lower in IIH (CSF and urine) and correlated with intracranial pressure and headache severity. The lactate:pyruvate ratio was increased in CSF and serum of IIH patients compared to controls and decreased at 12 months. Baseline acetate was higher in IIH, correlated with headache severity and disability and was reduced at 12 months. Ketones 3-hydroxybutyrate and acetoacetate were altered in CSF at baseline in IIH and normalized at 12 months. That these metabolic disturbances were evident in CSF, serum, and urine of IIH patients suggested a pattern of global metabolic dysregulation. Furthermore, altered ketone body metabolites became normalized following therapeutic weight loss.

Senior author Dr. Alex Sinclair, professor of neurology at the University of Birmingham said, “The experiences that patients with IIH have are significant and without being picked up can have serious consequences including sight loss. This is why this research is so important. We are identifying markers that can help to both identify a way to diagnose IIH, as well as provide a much better understanding of the root causes of the condition.

The study was published in the September 8, 2022, online edition of the journal Neurology.

Related Links:
University of Birmingham

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more